Logo image of SMMT

SUMMIT THERAPEUTICS INC (SMMT) Stock Fundamental Analysis

USA - NASDAQ:SMMT - US86627T1088 - Common Stock

18.16 USD
-0.02 (-0.11%)
Last: 11/10/2025, 1:44:57 PM
Fundamental Rating

3

SMMT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SMMT as it has an excellent financial health rating, but there are worries on the profitability. SMMT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SMMT has reported negative net income.
In the past year SMMT has reported a negative cash flow from operations.
In the past 5 years SMMT always reported negative net income.
In the past 5 years SMMT always reported negative operating cash flow.
SMMT Yearly Net Income VS EBIT VS OCF VS FCFSMMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

SMMT has a Return On Assets (-50.81%) which is comparable to the rest of the industry.
SMMT has a better Return On Equity (-56.93%) than 63.09% of its industry peers.
Industry RankSector Rank
ROA -50.81%
ROE -56.93%
ROIC N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
SMMT Yearly ROA, ROE, ROICSMMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SMMT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMMT Yearly Profit, Operating, Gross MarginsSMMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for SMMT has been increased compared to 1 year ago.
SMMT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SMMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SMMT Yearly Shares OutstandingSMMT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SMMT Yearly Total Debt VS Total AssetsSMMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 168.65 indicates that SMMT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 168.65, SMMT belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
SMMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 168.65
ROIC/WACCN/A
WACCN/A
SMMT Yearly LT Debt VS Equity VS FCFSMMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

SMMT has a Current Ratio of 10.15. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
SMMT's Current ratio of 10.15 is amongst the best of the industry. SMMT outperforms 81.92% of its industry peers.
A Quick Ratio of 10.15 indicates that SMMT has no problem at all paying its short term obligations.
The Quick ratio of SMMT (10.15) is better than 81.92% of its industry peers.
Industry RankSector Rank
Current Ratio 10.15
Quick Ratio 10.15
SMMT Yearly Current Assets VS Current LiabilitesSMMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SMMT have decreased strongly by -122.22% in the last year.
EPS 1Y (TTM)-122.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-287.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 47.18% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-323.7%
EPS Next 2Y-81.57%
EPS Next 3Y-42.91%
EPS Next 5Y47.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SMMT Yearly Revenue VS EstimatesSMMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B
SMMT Yearly EPS VS EstimatesSMMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SMMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMMT Price Earnings VS Forward Price EarningsSMMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMMT Per share dataSMMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

SMMT's earnings are expected to decrease with -42.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-81.57%
EPS Next 3Y-42.91%

More info and screens

0

5. Dividend

5.1 Amount

SMMT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUMMIT THERAPEUTICS INC

NASDAQ:SMMT (11/10/2025, 1:44:57 PM)

18.16

-0.02 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-20 2025-10-20/bmo
Earnings (Next)02-23 2026-02-23/bmo
Inst Owners13.57%
Inst Owner Change2.48%
Ins Owners84.35%
Ins Owner Change2.47%
Market Cap13.49B
Revenue(TTM)N/A
Net Income(TTM)-221.31M
Analysts79.09
Price Target32.71 (80.12%)
Short Float %27.75%
Short Ratio7.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.94%
Min EPS beat(2)-17.64%
Max EPS beat(2)3.77%
EPS beat(4)2
Avg EPS beat(4)-13.56%
Min EPS beat(4)-42.31%
Max EPS beat(4)3.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.97%
PT rev (3m)-5.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-22.64%
EPS NY rev (3m)-222.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 34.7
P/tB 34.87
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.81%
ROE -56.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.15
Quick Ratio 10.15
Altman-Z 168.65
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)90.01%
Cap/Depr(5y)64.02%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-122.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-287.5%
EPS Next Y-323.7%
EPS Next 2Y-81.57%
EPS Next 3Y-42.91%
EPS Next 5Y47.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.58%
EBIT Next 3Y-39.27%
EBIT Next 5YN/A
FCF growth 1Y-85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.13%
OCF growth 3YN/A
OCF growth 5YN/A

SUMMIT THERAPEUTICS INC / SMMT FAQ

Can you provide the ChartMill fundamental rating for SUMMIT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SMMT.


What is the valuation status of SUMMIT THERAPEUTICS INC (SMMT) stock?

ChartMill assigns a valuation rating of 0 / 10 to SUMMIT THERAPEUTICS INC (SMMT). This can be considered as Overvalued.


What is the profitability of SMMT stock?

SUMMIT THERAPEUTICS INC (SMMT) has a profitability rating of 1 / 10.


How financially healthy is SUMMIT THERAPEUTICS INC?

The financial health rating of SUMMIT THERAPEUTICS INC (SMMT) is 8 / 10.